Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13167052 | 0.98 | KDM4E (0.42) | KDM4EGLAATMRXFP1ALDH1A1 | |
| SCHEMBL31516455 | 0.98 | KDM4E (0.42) | KDM4EGLAATMRXFP1ALDH1A1 | |
| SCHEMBL3565425 | 0.82 | ALDH1A1 (0.44) | KDM4EALDH1A1GAAHPGDJAK2 | |
| SCHEMBL28674155 | 0.79 | JAK2 (0.44) | KDM4ERXFP1ALDH1A1MAPTJAK2 | |
| SCHEMBL30731021 | 0.75 | ALDH1A1 (0.46) | KDM4EGLAATMRXFP1ALDH1A1 | |
| SCHEMBL22554154 | 0.75 | ALDH1A1 (0.46) | KDM4EGLAATMRXFP1ALDH1A1 | |
| SCHEMBL24672007 | 0.73 | SLC22A12 (0.39) | RXFP1ALDH1A1MAPTHPGDSLC22A12 | |
| SCHEMBL12410481 | 0.73 | SELE (0.35) | KDM4EALDH1A1HPGDSLC22A12 | |
| SCHEMBL17148436 | 0.71 | SELE (0.34) | ALDH1A1SLC22A12 | |
| SCHEMBL5560155 | 0.71 | ADORA2A (0.35) | ALDH1A1GAAMAPTSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781664-B1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE INC (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-8470850-B2 | Inhibitors of VEGF receptor and HGF receptor signalling | METHYLGENE INC. (CA) | 2013-06-25 | — | — | US | disclosed |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | METHYLGENE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-7790729-B2 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE INC. (CA) | 2010-09-07 | — | — | US | disclosed |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | 92229129 QUEBEC INC. (CA) | 2010-08-26 | — | — | US | disclosed |
| US-7772247-B2 | Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor | METHYLGENE INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | METHYLGENE, INC. | 2006-12-21 | — | — | US | disclosed |
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. (CA) | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074056-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | KDM4E 4094/4885GLA 2918/4885ATM 1248/4885 |
| US-20060287343-A1 | INHIBITORS OF VEGF RECEPTOR AND HGF RECEPTOR SIGNALING | HGF, MET, FLT1 | KDM4E 4094/4885GLA 2918/4885ATM 1248/4885 |
| US-20100249145-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signaling | HGF, MET, FLT1 | KDM4E 4094/4885GLA 2918/4885ATM 1248/4885 |
| US-20100216766-A1 | Inhibitors of VEGF Receptor and HGF Receptor Signalling | HGF, MET, FLT1 | KDM4E 4091/4885GLA 3049/4885ATM 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.